Quantcast
Bioengineers Close To Creating Painkillers Without Using

Bioengineers Close To Creating Painkillers Without Using Opium From Poppies

By Tom Abate, Stanford School of Engineering A decade-long effort in genetic engineering is close to creating yeast that makes palliative medicines in stainless steel vats. For centuries poppy plants have been grown to provide opium, the...

Latest Hydrocodone Stories

2014-08-28 23:17:30

Controversial Hydrocodone-Based Painkiller Zohydro contains strong potential for addiction and as a substitute for OxyContin and heroin abuse. Aid in Recovery calls for the removal of the drug from the market. (PRWEB) August 28, 2014 Aid in Recovery, a full service drug and alcohol treatment center, released a statement today regarding the potential for abuse of a dangerous new painkiller, Zohydro, which is marketed to chronic pain sufferers. The drug, an extended-release painkiller that...

2014-08-06 20:23:58

Daiichi Sankyo and Charleston Laboratories will collaborate on development and commercialization; Charleston will supply all products and retain an option to co-promote in the United States TOKYO, PARSIPPANY, N.J. and JUPITER, Fla., Aug. 6, 2014 /PRNewswire/ -- Daiichi Sankyo and Charleston Laboratories, Inc., through its wholly owned subsidiary LOCL Pharma, Inc., announced today that the parties have entered into a strategic collaboration for the development and U.S....

2014-07-31 23:14:43

CR urges U.S. Food and Drug Administration to take stronger steps to reduce the dangers of pain-relief medications YONKERS, NY (PRWEB) July 31, 2014 Some pain relief medications can be as addictive as heroin and are rife with deadly side effects. Every day, 46 people in the U.S. die from legal pain pills and for each death, more than 30 people are admitted to an emergency room because of opioid complications. Consumer Reports has taken a close look at the dangers of prescription and...

2014-07-29 08:34:16

WAYNE, Pa., July 29, 2014 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet") today announced that its second quarter financial results will be released on Tuesday, August 12, 2014. Following the announcement, Egalet's management will host a live conference call and webcast at 8:30 am Eastern Time to review the Company's financial and operating results and provide a general business update. The live webcast and a replay may be accessed by visiting Egalet's website. Please...

2014-07-08 08:31:18

Anticipated FDA action set for October 2014 STAMFORD, Conn., July 8, 2014 /PRNewswire/ -- Purdue Pharma L.P. announced that the U.S. Food & Drug Administration (FDA) has granted Priority Review designation for the company's once-daily, single-entity hydrocodone bitartrate tablet (HYD). This investigational pain medication was formulated to incorporate abuse-deterrent properties designed to make the product more difficult to manipulate for the purpose of misuse or abuse by...

2014-06-03 08:32:29

Multi-Tranche Financing Provides Sufficient Funding to Take KP201 Through and Beyond Potential FDA Approval and Enables KemPharm to Advance its Full Pipeline of Abuse-Deterrent Prodrugs CORALVILLE, Iowa, June 3, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that it has entered into a $60 million financing agreement with an investment fund managed by...

2014-05-28 08:32:01

Controlled Substance Analgesic Combination Product Uses Depomed's Proprietary Acuform® Technology NEWARK, Calif., May 28, 2014 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) announced today that the U. S. Food and Drug Administration (FDA) has accepted for filing a New Drug Application (NDA) from Mallinckrodt (NYSE: MNK) for MNK-155. MNK-155 is an investigational extended-release oral formulation of hydrocodone and acetaminophen that has been studied for the management of moderate to...

2014-05-21 08:28:28

CutisPharma has moved to a larger facility to support growth WILMINGTON, Mass., May 21, 2014 /PRNewswire/ -- CutisPharma, Inc. announced its move to a new location at 841 Woburn St. Wilmington, MA. "We are pleased to announce our relocation to a larger facility to support our record growth," said Dr. Indu Muni, founder, chairman, and CEO of CutisPharma, Inc. "The move will help to maintain our expansion, particularly in the areas of Research and Development, Customer Service, and...

2014-05-07 08:33:35

CUPERTINO, Calif., May 7, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President and CEO of DURECT Corporation, will be an industry speaker at the Bay Area Prescription Drug Abuse Summit on May 7, 2014 in San Francisco. The summit is an effort to bring together senior policymakers, medical professionals, educators, local, state and federal law enforcement and the community to seek solutions to this problem and to raise awareness of the...

2014-04-30 23:21:39

New hydrocodone painkiller could come with an increased risk of addiction. Fort Lauderdale, Fla. (PRWEB) April 30, 2014 A brand-new painkiller has been released, and it could pose a very serious threat to the public. Zohydro is the first painkiller that is made up only of hydrocodone, and available dosage amounts go as high as 50 milligrams. This is five times as much as comparable drugs. Destination Hope's Florida drug rehab is concerned that a lack of education and easy access to...


Word of the Day
cock-a-hoop
  • Exultant; jubilant; triumphant; on the high horse.
  • Tipsy; slightly intoxicated.
This word may come from the phrase 'to set cock on hoop,' or 'to drink festively.' Its origin otherwise is unclear. A theory, according to the Word Detective, is that it's a 'transliteration of the French phrase 'coq a huppe,' meaning a rooster displaying its crest ('huppe') in a pose of proud defiance.' Therefore, 'cock-a-hoop' would 'liken a drunken man to a boastful and aggressive rooster.'
Related